Efficacy and safety of combination therapy with mirodenafil and α 1-blocker for benign prostatic hyperplasia-induced lower urinary tract symptoms accompanied by erectile dysfunction: A multicenter, open-label, prospective study

International Journal of Impotence Research

Volumn 23, Issue 6, 2011, Pages 249-256

  Lee, J Y ^a   Cho, S Y ^b   Oh, C Y ^c   Ha, U S ^d   Lee, S H ^e   Park, S Y ^a   Moon, H S ^a   Lee, S W ^a  

^a Hanyang University College of Medicine   (South Korea)

^b Inje University College of Medicine   (South Korea)

^c Hallym University College of Medicine   (South Korea)

^d The Catholic University of Korea College of Medicine   (South Korea)

^e Yonsei University College of Medicine   (South Korea)

Author keywords

adrenergic alpha 1 receptor antagonists; erectile dysfunction; mirodenafil; prostatic hyperplasia

Indexed keywords

ALFUZOSIN; MIRODENAFIL; TAMSULOSIN;

ADULT; ARTICLE; BLOOD PRESSURE; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; ERECTILE DYSFUNCTION; FLUSHING; HEADACHE; HEART RATE; HEMODYNAMIC PARAMETERS; HUMAN; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MALE; MICTURITION; MULTICENTER STUDY; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; QUALITY OF LIFE; RESIDUAL URINE; SEXUAL FUNCTION; SIDE EFFECT; URINE FLOW RATE; URODYNAMICS;

ADRENERGIC ALPHA-1 RECEPTOR ANTAGONISTS; BLOOD PRESSURE; DRUG THERAPY, COMBINATION; ERECTILE DYSFUNCTION; HEART RATE; HUMANS; HYPOTENSION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATIC HYPERPLASIA; PYRIMIDINONES; QUALITY OF LIFE; SULFONAMIDES; URINATION DISORDERS; UROLOGIC DISEASES;

EID: 80955144299     PISSN: 09559930     EISSN: 14765489     Source Type: Journal    
DOI: 10.1038/ijir.2011.34     Document Type: Article

References (31)

1. Rosen R, Altwein J, Boyle P, Kirby RS, Lukacs B, Meuleman E et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol 2003; 44: 637-649. (Pubitemid 37542920)
2. Braun M, Wassmer G, Klotz T, Reifenrath B, Mathers M, Engelmann U. Epidemiology of erectile dysfunction: results of the 'Cologne Male Survey'. Int J Impot Res 2000; 12: 305-311. (Pubitemid 32175951)
3. Boyle P, Robertson C, Mazzetta C, Keech M, Hobbs R, Fourcade R et al. The association between lower urinary tract symptoms and erectile dysfunction in four centres: the UrEpik study. BJU Int 2003; 92: 719-725. (Pubitemid 37475814)
4. McVary KT, Foley J, Slawin K. The long-term effects of doxazosin, finasteride, and the combination on sexual function in men participating in the MTOPS trial. J Urol 2004; 171: 1194.
5. Deedwania PC. Mechanisms of endothelial dysfunction in the metabolic syndrome. Curr Diab Rep 2003; 3: 289-292. (Pubitemid 38906784)
6. Khan MA, Thompson CS, Dashwood MR, Mumtaz FH, Morgan RJ, Mikhailidis DP. Endothelin-1 and nitric oxide in the pathogenesis of urinary tract disorders secondary to bladder outlet obstruction. Curr Vasc Pharmacol 2003; 1: 27-31.
7. Gradini R, Realacci M, Ginepri A, Naso G, Santangelo C, Cela O et al. Nitric oxide synthases in normal and benign hyperplastic human prostate: immunohistochemistry and molecular biology. J Pathol 1999; 189: 224-229. (Pubitemid 29448917)
8. Yassin A, Saad F, Hoesl CE, Traish AM, Hammadeh M, Shabsigh R. Alpha-adrenoceptors are a common denominator in the pathophysiology of erectile function and BPH/LUTS-implications for clinical practice. Andrologia 2006; 38: 1-12.
9. Carson CC. Combination of phosphodiesterase-5 inhibitors and alpha-blockers in patients with benign prostatic hyper-plasia: treatments of lower urinary tract symptoms, erectile dysfunction, or both? BJU Int 2006; 97(Suppl 2): 39-43; discussion 44-35. (Pubitemid 43356995)
10. Naderi N, Mochtar CA, de la Rosette JJ. Real life practice in the management of benign prostatic hyperplasia. Curr Opin Urol 2004; 14: 41-44. (Pubitemid 39186213)
11. Giannitsas K, Mitropoulos D, Konstantinopoulos A, Athana-sopoulos A, Perimenis P. Phosphodiesterase-5 inhibitors in the treatment of lower urinary tract symptoms and benign prostatic hyperplasia. Expert Opin Pharmacother 2008; 9: 1687-1693.
12. Roehrborn CG, McConnell JD, Barry MJ. AUA guidelines on the management of benign prostatic hyperplasia (BPH). J Urol 2003; 170: 530-547.
13. Hatzimouratidis K, Amar E, Eardley I, Giuliano F, Hatzichris-tou D, Montorsi F et al. Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. Eur Urol 2010; 57: 804-814.
14. Wang C. Phosphodiesterase-5 inhibitors and benign prostatic hyperplasia. Curr Opin Urol 2010; 20: 49-54.
15. Oger S, Behr-Roussel D, Gorny D, Lecoz O, Lebret T, Denoux Y et al. Combination of doxazosin and sildenafil exerts an additive relaxing effect compared with each compound alone on human cavernosal and prostatic tissue. J Sex Med 2009; 6: 836-847.
16. Shin HI, Lee J, Kim DK. Synthesis of 5-ethyl-2-{5-[4-(2-hydroxyethyl) piperazin-1-ylsulfonyl]-2-n-propoxyphenyl}-7-n-propyl-3, 5-dihydro-4H-pyrrolo [3, 2-d]-[2-14C] pyrimid. J Labelled Comp Radiopharm 2006; 49: 1141-1149.
17. Paick JS, Choi HK, Kim SC, Ahn TY, Kim JJ, Park JK et al. Efficacy and safety of oral SK3530 for the treatment of erectile dysfunction in Korean men: a multicenter, randomized, double-blind, placebo-controlled, fixed dose, parallel group clinical trial. Asian J Androl 2008; 10: 791-798.
18. Lee J, Yoo HH, Rhim KJ, Sohn DR, Kim DH. Metabolism and excretion of 5-ethyl-2-{5-[4-(2-hydroxyethyl) piperazine-1-sul-fonyl]-2-propoxyphenyl}-7- propyl-3, 5-dihydropyrrolo [3, 2-d]-pyrimidin-4-one (SK3530) in rats. Rapid Commun Mass Spectrom 2007; 21: 1139-1149.
19. Paick JS, Kim JJ, Kim SC, Moon KH, Min KS, Park K et al. Efficacy and safety of mirodenafil in men taking antihyper-tensive medications. J Sex Med 2010; 7: 3143-3152.
20. Auerbach SM, Gittelman M, Mazzu A, Cihon F, Sundaresan P, White WB. Simultaneous administration of vardenafil and tamsulosin does not induce clinically significant hypotension in patients with benign prostatic hyperplasia. Urology 2004; 64: 998-1003; discussion 1003-1004. (Pubitemid 39469521)
21. Giuliano F, Kaplan SA, Cabanis MJ, Astruc B. Hemodynamic interaction study between the alpha1-blocker alfuzosin and the phosphodiesterase-5 inhibitor tadalafil in middle-aged healthy male subjects. Urology 2006; 67: 1199-1204. (Pubitemid 43818091)
22. Nieminen T, Tammela TL, Koobi T, Kahonen M. The effects of tamsulosin and sildenafil in separate and combined regimens on detailed hemodynamics in patients with benign prostatic enlargement. J Urol 2006; 176(Part 1): 2551-2556. (Pubitemid 44665956)
23. Kaplan SA, Gonzalez RR, Te AE. Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. Eur Urol 2007; 51: 1717-1723. (Pubitemid 46634750)
24. Bechara A, Romano S, Casabe A, Haime S, Dedola P, Hernandez C et al. Comparative efficacy assessment of tamsulosin vs tamsulosin plus tadalafil in the treatment of LUTS/BPH. Pilot study. J Sex Med 2008; 5: 2170-2178.
25. Liguori G, Trombetta C, De Giorgi G, Pomara G, Maio G, Vecchio D et al. Efficacy and safety of combined oral therapy with tadalafil and alfuzosin: an integrated approach to the management of patients with lower urinary tract symptoms and erectile dysfunction. Preliminary report. J Sex Med 2009; 6: 544-552.
26. Chung BH, Lee JY, Lee SH, Yoo SJ, Lee SW, Oh CY. Safety and efficacy of the simultaneous administration of udenafil and an alpha-blocker in men with erectile dysfunction concomitant with BPH/LUTS. Int J Impot Res 2009; 21: 122-128.
27. Tuncel A, Nalcacioglu V, Ener K, Aslan Y, Aydin O, Atan A. Sildenafil citrate and tamsulosin combination is not superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. World J Urol 2010; 28: 17-22.
28. Roumeguere T, Zouaoui Boudjeltia K, Hauzeur C, Schulman C, Vanhaeverbeek M, Wespes E. Is there a rationale for the chronic use of phosphodiesterase-5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyper-plasia? BJU Int 2009; 104: 511-517.
29. Kang DH, Lee JY, Park SY, Moon HS, Jeong TY, Yoo TK et al. Efficacy and safety of tadalafil 5mg Administered once daily in Korean men with erectile dysfunction: a prospective, multicenter study. Korean J Urol 2010; 51: 647-652.
30. Shindel AW. 2009 update on phosphodiesterase type 5 inhibitor therapy part 1: recent studies on routine dosing for penile rehabilitation, lower urinary tract symptoms, and other indications (CME). J Sex Med 2009; 6: 1794-1808
31. quiz 1793, 1809-1710.